CEO Pravin Dugel described 2025 as "a transformative year for Ocular Therapeutix" and highlighted the advancement of two registrational studies in wet AMD, SOL-1 and SOL-R. Dugel announced, "SOL-R has ...
Non-inferiority trials are a valuable type of clinical trial to evaluate new treatments that might have differing benefits. Such trials are increasingly used, but have methodological challenges in ...
SOL-1 Phase 3 superiority trial results remain masked to date SOL-1 data expected to be presented at the 49 th Macula Society Annual Meeting Ocular plans to submit NDA for AXPAXLI™ in wet AMD based on ...
The MarketWatch News Department was not involved in the creation of this content. Darius M. Moshfeghi, Chief of the Retina Division at Byers Eye Institute of Stanford University School of Medicine ...
Detailed SOL-1 data to be presented at the 49(th) Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), an integrated ...
Please provide your email address to receive an email when new articles are posted on . The tyrosine kinase inhibitor maintained vision at week 36 in the SOL-1 trial. Axpaxli demonstrated positive ...
BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (OCUL) (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results